ÂÜÀòÂÒÂ×

Rabab Nasrallah, PhD, is an experienced investment professional at Earlybird Venture Capital since January 2020, with additional roles including Member of the Board of Directors at Grey Wolf Therapeutics and Board Observer positions at GEMMA Biotherapeutics, ImCheck Therapeutics, Prothea Technologies, and Priothera SAS. Prior experience includes research engagement and program management at INCUBATE, as well as a strategy research associate role at The George Institute for Global Health. Rabab also served as a committee member for the Babraham Institute Knowledge Exchange and Commercialisation and held a postdoctoral research scientist position at the University of Cambridge. Academic credentials include a PhD in Stem Cell and Developmental Biology from UNSW and a visiting scientist role at The University of Manchester.